Initial process of polyglutamine aggregate formation in vivo.

Area of Science:

• Neurodegenerative diseases
• Protein aggregation
• Molecular biology

Background:

• Polyglutamine expansion in proteins causes inherited neurodegenerative diseases.
• Expanded polyglutamine tracts exhibit toxicity to neural cells and form aggregates.
• Yeast models are utilized to study the in vivo mechanisms of polyglutamine aggregate formation.

Purpose of the Study:

• To investigate the in vivo process of polyglutamine aggregate formation.
• To understand the role of cellular factors in polyglutamine aggregation kinetics.

Main Methods:

• Expression of polyglutamine tracts in yeast.
• Gel filtration analysis to characterize soluble polyglutamine forms.
• Assessment of aggregate formation kinetics under varying conditions (tract length, guanidine hydrochloride treatment, Hsp104 presence).

Main Results:

• Polyglutamine tracts transition from soluble to insoluble forms after a lag period.
• Decreasing tract length or guanidine hydrochloride treatment slows aggregation.
• Hsp104 is essential in vivo for the soluble-to-insoluble conversion, with its dependency varying by tract length.

Conclusions:

• Polyglutamine aggregate formation efficiency depends on a balance between polyglutamine tract length, Hsp104 activity, and expression levels.
• Hsp104 plays a critical role in initiating aggregation in vivo.
• The study provides insights into the in vivo kinetics and regulation of polyglutamine aggregation.